Health
STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes – medwireNews
The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors…
medwireNews: The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.
Improvements in glycemic control were relatively small, with glycated hemoglobin (HbA1c) levels falling by an average of 1.6% (17.5 mmol/mol) among people randomly assigned to receive weekly semaglutide 2.4 mg for 68 weeks and 1.5% (15.9 mmol/mol) among those given…
-
Business20 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News20 hours agoQueensland’s nurses and midwives ramp up industrial action as pay negotiations break down
-
Noosa News20 hours agoQueensland racing, campdrafting events to continue after Hendra detection
-
Noosa News21 hours agoBroncos staffer who guided Mam through crash crisis admits to drink-driving